Nuvalent to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference PR Newswire CAMBRIDGE, Mass., Feb. 1, 2024 CAMBRIDGE, Mass. , Feb. 1, 2024 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today announced that James Porter , Ph.D., Chief Executive Officer, and Alexandra Balcom , Chief Financial Officer, will participate in a...